Alnuctamab for Refractory SLE (LATTE Study)

• Status: NOT_YET_RECRUITING
• Trial end date: 2027-12-01

Summary

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

• Phase: PHASE1

Details

• Lead Sponsor: Icahn School of Medicine at Mount Sinai